From the Department for Anesthesia, Interdisciplinary Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital (AG, TG, SD-K, AU, OB) and Basel Institute for Clinical Epidemiology and Biostatistics (SD-K), University of Basel, Basel, Switzerland.
Eur J Anaesthesiol. 2021 Jul 1;38(7):751-757. doi: 10.1097/EJA.0000000000001399.
Ryanodine receptor type 1 (RYR1) sequence variants are pathogenic for malignant hyperthermia. Variant carriers have a subtle increase in resting myoplasmic calcium concentration compared with nonaffected individuals, but whether this has metabolic effects in daily life is unknown.
We analysed the potential effect of malignant hyperthermia-pathogenic RYR1 sequence variants on BMI as a single factor. Due to the heterogeneity of genetic variants predisposing to malignant hyperthermia, and to incomplete information about their regional distribution, we describe the prevalence of RYR1 variants in our population.
A retrospective cohort study.
A single University hospital.
Patients from malignant hyperthermia families with pathogenic RYR1 sequence variants were selected if BMI was available.
BMI values were compared amongst malignant hyperthermia susceptible (MHS) and malignant hyperthermia-negative individuals using hierarchical multivariable analyses adjusted for age and sex and considering family clustering. Variant prevalence was calculated.
The study included 281 individuals from 42 unrelated malignant hyperthermia families, 109 of whom were MHS and carriers of the familial RYR1 sequence variants. Median [IQR] BMI in MHS individuals with pathogenic RYR1 variants was 22.5 kg m-2 [21.3 to 25.6 kg m-2]. In malignant hyperthermia-negative individuals without variants, median BMI was 23.4 kg m-2 [21.0 to 26.3 kg m-2]. Using multivariable regression adjusted for age and sex, the mean difference was -0.73 (95% CI -1.51 to 0.05). No carrier of a pathogenic RYR1 sequence variant was found to have BMI higher than 30 kg m-2. Only 10 RYR1 variants from the list of the European MH Group were found in our cohort, the most common being p.Val2168Met (39% of families), p.Arg2336His (24%) and p.Arg614Cys (12%).
The observed tendency towards lower BMI values in carriers of malignant hyperthermia-pathogenic RYR1 sequence variants points to a possible protective effect on obesity. This study confirms regional differences of the prevalence of malignant hyperthermia-pathogenic RYR1 sequence variants, with just three variants covering 75% of Swiss MHS families.
This manuscript is based on a retrospective analysis.
Ryanodine 受体 1 型(RYR1)序列变异与恶性高热有关。与未受影响的个体相比,变异携带者的静息肌浆钙离子浓度略有升高,但在日常生活中是否存在代谢影响尚不清楚。
我们分析了恶性高热致病 RYR1 序列变异作为单一因素对 BMI 的潜在影响。由于导致恶性高热的遗传变异存在异质性,并且对其区域分布的信息不完全,因此我们描述了 RYR1 变异在我们人群中的流行情况。
回顾性队列研究。
一家大学医院。
如果有 BMI 数据,我们选择来自恶性高热家族且携带致病性 RYR1 序列变异的患者。
使用分层多变量分析比较易患恶性高热(MHS)和恶性高热阴性个体的 BMI 值,该分析调整了年龄和性别,并考虑了家族聚集性。计算了变异的患病率。
该研究纳入了 42 个无关的恶性高热家族的 281 名个体,其中 109 名是 MHS 患者且携带家族性 RYR1 序列变异。携带致病性 RYR1 变异的 MHS 个体的 BMI 中位数[IQR]为 22.5kg/m²[21.3 至 25.6kg/m²]。在无变异的恶性高热阴性个体中,BMI 中位数为 23.4kg/m²[21.0 至 26.3kg/m²]。使用调整了年龄和性别的多变量回归,平均差异为-0.73(95%CI-1.51 至 0.05)。未发现携带致病性 RYR1 序列变异的个体 BMI 高于 30kg/m²。在我们的队列中仅发现了欧洲 MH 组列出的 10 种 RYR1 变异,最常见的是 p.Val2168Met(39%的家族)、p.Arg2336His(24%)和 p.Arg614Cys(12%)。
携带恶性高热致病 RYR1 序列变异的个体 BMI 值观察到的下降趋势表明其对肥胖可能具有保护作用。本研究证实了恶性高热致病 RYR1 序列变异的流行存在区域性差异,只有三种变异覆盖了瑞士 75%的 MHS 家族。
本研究基于回顾性分析。